Background Neonatal hypoglycaemia is common, and a preventable cause of brain damage. Dextrose gel is used to reverse hypoglycaemia in individuals with diabetes; however, little evidence exists for its use in babies. We aimed to assess whether treatment with dextrose gel was more eff ective than feeding alone for reversal of neonatal hypoglycaemia in at-risk babies.
Introduction
Neonatal hypoglycaemia is important because it is a common disorder, which is associated with brain injury and poor neurodevelopmental outcome. [1] [2] [3] Although the defi nition of neonatal hypoglycaemia is controversial, 4 thresholds for treatment have been established 5 and are used in clinical practice. 6 Neonatal hypoglycaemia aff ects as many as 5-15% of otherwise healthy babies 5, 7 and is widespread in resource-poor countries. 8, 9 Furthermore, prevalence of the disorder is increasing because of the increasing incidence of preterm birth 10 and maternal factors, such as diabetes 11 and obesity, 12 which can predispose babies to hypoglycaemia. Little evidence exists to guide treatment and repeated calls have been made to develop evidence-based guidelines for the treatment of neonatal hypoglycaemia. 5, 7, 13, 14 Treatment choices vary dependent on the baby's birthweight and gestational age. In late preterm and term babies, initial management focuses on feeding and increased monitoring, requiring repeated and painful blood tests. If blood glucose concentration remains low, admission to the newborn intensive-care unit for intravenous glucose is usually indicated. 15 Such admission usually means that mother and baby are separated, which can delay the establishment of breastfeeding.
In addition to intravenous glucose, 40% dextrose gel is another less commonly used treatment. Potential advantages of dextrose gel are that it keeps mother and baby together while treatment is provided, is easy to administer, and is low cost. Oral carbohydrate is fi rst-line treatment for low blood glucose concentrations in the con scious diabetic child or adult, 16 and sublingual glucose is as eff ective as intravenous glucose for treatment of hypo glycaemic children with malaria. 17 Two small observational studies 18, 19 in babies aged between 28 weeks' and 42 weeks' gestation have reported improvement in blood glucose concentrations after massaging of 200 mg/kg dextrose gel into the buccal mucosa. However, a randomised trial, 20 in which 75 babies with hypoglycaemia were randomly assigned to a feed or feed plus 400 mg/kg dextrose gel on the fi rst day after birth, showed no diff erences in blood glucose concentrations at 15 min and 30 min after treatment. Furthermore, formula-fed babies assigned to the dextrose-gel group suckled a smaller volume during the subsequent feed than did those in the feed-alone group. 20 Therefore, the role of dextrose gel in the management of neonatal hypoglycaemia remains unclear.
We assessed whether treatment with 40% dextrose gel was more eff ective than feeding alone for reversal of neonatal hypoglycaemia in at-risk late preterm and term babies.
Methods

Study design and participants
We undertook this randomised, double-blind, placebocontrolled study at a tertiary referral centre (Waikato Women's Hospital) in Hamilton, New Zealand, between Dec 1, 2008, and Nov 31, 2010. Eligible babies were born at 35 weeks' gestation or older, aged 48 h or younger, and at risk of neonatal hypoglycaemia. Risk factors were being the infant of a diabetic mother (gestational, type 1, or type 2 diabetes), being preterm (35 or 36 weeks' gestation), being small (birthweight <10th centile or <2500 g) or large (birthweight >90th centile or >4500 g), or other reasons such as poor feeding. Exclusion criteria were any previous treatment for neonatal hypoglycaemia, serious congenital malformation, terminal disorders, or skin abnormalities that would prevent use of the continuous glucose monitor. A researcher contacted women identifi ed as likely to give birth to an eligible baby before birth; those not recruited before birth were contacted as soon as possible after the birth.
The study was approved by the Northern Y Ethics Committee and all mothers provided written informed consent. The study protocol is available online.
Randomisation and masking
We used computer-generated blocked randomisation, with variable block sizes, to assign babies (1:1) who became hypoglycaemic to either 40% dextrose gel or placebo gel. Randomisation was stratifi ed by maternal diabetes (yes or no) and birthweight (small, appropriate, or large). We assigned twins independently. The researcher entered demographic data into a computer that provided a randomisation number corresponding to a numbered treatment pack containing six labelled syringes, each containing 3 mL of the same gel: either 40% dextrose gel or 2% carboxymethyl cellulose placebo gel, which was identical in appearance. Study packs were prepared by the hospital pharmacist, who had no other involvement in the study. Clinicians, families, and all study investigators were all masked to group allocation until data analysis was complete.
Procedures
The researcher or midwife dried the baby's mouth with gauze, massaged 200 mg/kg (0·5 mL/kg) gel into the buccal mucosa, and the baby was encouraged to feed. If feeding was poor, the baby was given expressed breastmilk or formula by syringe, according to maternal wishes. The blood glucose concentration was measured 30 min after gel administration and, if the baby remained hypoglycaemic or hypoglycaemia recurred later, treatment was repeated with another syringe from the allocated pack. Up to six doses of gel could be given over 48 h.
We measured blood glucose concentrations according to clinical guidelines in our hospital 21 on samples obtained by heel lances 1 h after birth, then every 3-4 h before feeds for the fi rst 24 h, then every 6-8 h for the subsequent 24 h. All blood glucose concentrations were measured by the glucose oxidase method (Radiometer, ABL800 FLEX, Copenhagen, Denmark). A continuous glucose monitor (CGMS System Gold, Medtronic, MiniMed, Northridge, CA, USA) was placed sub cutaneously in the lateral thigh as soon as possible after birth, or after recruitment if this was after birth. 22 The monitor remained in place for at least 48 h or for up to 7 days until hypoglycaemia was no longer a clinical concern. These monitors are safe and reliable in newborn babies, including at low glucose concentrations. 22, 23 Interstitial glucose concentrations cannot be viewed in real time, ensuring clinical practice was not aff ected by the results.
Mothers were encouraged to provide skin-to-skin contact and feed the baby within the fi rst hour after birth. Before birth many mothers expressed and stored breastmilk, and when possible, babies who did not breastfeed adequately were given expressed breastmilk by syringe. Babies who were to be formula fed were off ered up to 60 mL/kg per day on day one, and 90 mL/kg per day on day two.
The primary outcome was treatment failure, defi ned as a blood glucose concentration of less than 2·6 mmol/L 30 min after the second of two doses of gel. Secondary outcomes were admission to the neo natal intensive-care unit; frequency of breastfeeding; total volume and frequency of expressed breastmilk and infant formula, intravenous dextrose, and dextrose gel in the fi rst 48 h; method of feeding 2 weeks after birth; incidence of rebound and recurrent hypogly caemia after successful treatment; time taken to achieve interstitial glucose concentrations of 2·6 mmol/L or more after treatment; and total duration of interstitial glucose concentrations of less than 2·6 mmol/L up to 48 h after birth. Hypoglycaemia was defi ned as a blood or interstitial glucose concentration of less than 2·6 mmol/L, which was the accepted clinical threshold for treatment 6 and the threshold for treatment used in our hospital. Episodes of hypoglycaemia were defi ned as one or more consecutive blood glucose concentrations of less than 2·6 mmol/L or two or more consecutive interstitial glucose concen trations of less than 2·6 mmol/L. Rebound hypoglycaemia was defi ned as an episode of hypoglycaemia within 6 h after successful treatment (blood or interstitial glucose ≥2·6 mmol/L for ≥1 h after treatment). Recurrent hypo glycaemia was defi ned as a further episode of hypo glycaemia after successful treatment, within 48 h after birth. Babies who met the criteria for treatment failure and remained hypoglycaemic were admitted to the neonatal intensive-care unit and treated with open-label dextrose gel, infant formula, or intravenous dextrose, according to clinical guidelines and clinician preference.
An independent data monitoring committee reviewed results after 100 babies had been randomised and recommended the study continue. The safety monitoring committee received reports of serious adverse events (death and seizures), and of other adverse events of severe hypoglycaemia (blood glucose concentration <1 mmol/L), hyperglycaemia (two consecutive blood glucose concentrations >8·0 mmol/L), culture proven sepsis, and infl ammation or swelling at the insertion site of the continuous glucose monitor.
Statistical analysis
A retrospective review of 91 babies at risk of neonatal hypoglycaemia born at our hospital in 2006 showed that 51 (56%) became hypoglycaemic, of whom nine (20%) remained hypoglycaemic after two doses of dextrose gel. We planned the study as a superiority trial with a onetailed design (α 0·05, β 0·2) and, with an allowance of 5% withdrawal, a sample size of 230 (115 per group) would be needed to detect a reduction in the rate of treatment failure from 35% in the placebo group to 20% in the dextrose gel group.
Data from the interstitial glucose monitors were downloaded with CGMS Solutions software (version 3.0C) and recalibrated with a previously reported algorithm 24 to optimise accuracy at low concentrations of blood glucose with use of Matlab (version 7.14 2012a). During preparation of the data analysis plan, and before unblinded analysis, we decided to use a standard two-sided analysis. Statistical analyses were on an intention-to-treat basis, and we allocated babies for whom primary outcome data were not available to the conservative outcome of treatment failure. Data were analysed with SAS Enterprise Guide (version 4·3) and are presented as median (range), mean (SD), relative risk (RR), or median diff erence and 95% CIs. We analysed normally distributed continuous variables with t tests; otherwise we used a Wilcoxon twosample test. We analysed feeding at 2 weeks of age with unordered generalised logistic regression with breastmilk as the reference group. We com pared rates of rebound and recurrent hypoglycaemia between groups with rate ratios that were calculated with OpenEpi (version 2.3.1).
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We adjusted the primary outcome for reasons why the baby was anticipated to be at risk of hypoglycaemia (maternal diabetes and birth weight) because randomisation was balanced across these categories. No other Data are mean (SD), median (range), and n (%), unless otherwise indicated. BMI=body-mass index.*Three mothers are in both columns because one twin was assigned to each treatment group (ie, n=227 mothers). †Many babies had more than one risk factor for hypoglycaemia. 
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report, nor decision to submit the manuscript for publication.
Results
The fi gure shows the trial profi le. Of 514 babies enrolled, 242 (47%) became hypoglycaemic and were ran domised. Five babies were randomised in error, leaving 237 for analysis: 118 (50%) in the dextrose group and 119 (50%) in the placebo group. Demographic and baseline charac teristics were similar between groups, although more boys were allocated to the placebo group (table 1) . Charac teristics were also similar in babies and their mothers who were enrolled but not randomised because they did not become hypoglycaemic (data not shown). Risk factors for hypoglycaemia were similar in both groups ( 432 doses of study gel were administered-215 in the dextrose group and 217 in the placebo gel group. In both groups babies received a median of two doses (range 1-5) of study gel of similar volume, resulting in those randomised to dextrose receiving a median of 0·3 g/kg (95% CI 0·2-1·0) dextrose (table 2) . Primary outcome data were available for 116 (98%) babies in the dextrose group, and 118 (99%) in the placebo group. For the remaining three babies, blood glucose concentration was not measured at the appropriate time so the primary outcome could not be measured (table 2) . Fewer babies in the dextrose group than in the placebo group met the criteria for treatment failure (table 2). Overall 100 (42%) of 237 babies were admitted to the neonatal intensive-care unit, of whom roughly half were admitted for treatment of hypoglycaemia (table 2) . Admission rates were similar in both treatment groups, but babies who received dextrose gel were less likely to be admitted for hypoglycaemia (table 2) . 40 (17%) babies needed additional treatment with dextrose. Babies in the dextrose group were less likely to receive additional dextrose than were those in the placebo group, but those who did receive intravenous dextrose had similar amounts (table 2) . 98% (n=220) of mothers intended to breastfeed, and almost all babies were breastfed (table 2). Babies in the dextrose group received expressed breastmilk less frequently and in smaller volumes than did those in the placebo group (table 2) . Babies in the dextrose gel group received fewer formula feeds than those in the placebo group, but the volume of formula feeds did not diff er signifi cantly between groups (table 2). At 2 weeks of age, fewer babies were formula feeding in the dextrose gel group than in the placebo group (5 [4%] vs 15 [13%]; RR 0·34. 95% CI 0·13-0·90; p=0·03).
175 (74%) of babies had continuous glucose monitoring: 88 (75%) in the dextrose group and 87 (73%) in the placebo group. However, only 76 gel treatments (38 in each group) could be analysed for the secondary outcomes that involved continuous glucose monitoring. Episodes of rebound hypoglycaemia were uncommon and similar in frequency in both groups (table 3) . Episodes of recurrent hypoglycaemia were less common in babies in the dextrose gel group than in those ran domised to placebo when measured by interstitial, but not blood, glucose concentrations (table 3) . The median time taken for interstitial glucose concentration to be restored was similar in both treatment groups, at 20·3 min (95% CI 0·2-215·4) in the dextrose group and 22·8 min (1·9-165·2) in the placebo group (median diff erence 4·9 min, 95% CI 4·4-19·4; p=0·13). The total duration of low interstitial glucose concentrations was not signifi cantly reduced by dextrose gel (table 3) .
Treatment with dextrose gel was well tolerated, with similar numbers of doses reported as tolerated in both groups (213 [99%] of 215 given dextrose and 211 [97%] of 217 given placebo). Furthermore, 113 mothers in each of the dextrose (97%) and placebo (96%) groups reported that gel treatment was an acceptable and easy treatment for their babies. We noted no serious adverse events. Three (3%) babies in the placebo group each had one blood glucose concentration of 0·9 mmol/L. No other adverse events were reported.
Prespecifi ed subgroup analysis showed no diff erences in response between babies with diff erent risk factors (data not shown). If the three babies for whom primary outcome was not available were excluded, fi ndings for treatment failure remained unchanged (14 [12%] of 116 babies in the dextrose gel and 28 [24%] of 118 in the placebo group; RR 0·51, 95% CI 0·28-0·92; p=0·03).
Discussion
Our fi ndings show that treatment with 40% dextrose gel is more eff ective than feeding alone for reversal of neonatal hypoglycaemia in at-risk late preterm and term babies in the fi rst 48 h after birth. Furthermore, babies who received Proportion of time (%) 3·0% (0·0 to 31·8) 6·1% (0·0 to 37·9) 1·8 -0·2 to 4·6 0·13 Data are n (%) or median (95% CI). *During the fi rst 48 h after birth for babies with at least 40 h of satisfactory continuous glucose monitoring. Table 3 : Rebound and recurrent hypoglycaemia in babies assigned to dextrose or placebo gel dextrose gel were less likely to be admitted to neonatal intensive-care units for management of hypoglycaemia, to receive additional dextrose or formula feeds, or to be formula fed at 2 weeks of age. Dextrose gel did not increase the risk of rebound or recurrent hypoglycaemia, was well tolerated, and was not associated with adverse eff ects. Dextrose gel has been recommended for the management of neonatal hypoglycaemia 26 and there are anecdotal reports of improvement in blood glucose concentration after dextrose gel absorption via the buccal mucosa. 18, 19 However, the only randomised trial of dextrose gel for neonatal hypoglycaemia reported that babies admitted to neonatal intensive care had no increases in blood glucose concentrations with 400 mg/kg gel. 20 Our study is the fi rst report in babies showing that buccal dextrose gel is a safe eff ective treatment for management of hypoglycaemia (panel).
One early concern was the possibility that dextrose gel might adversely aff ect breastfeeding, because receipt of any supplements in the neonatal period is reported to delay the establishment of, and decrease the duration of, breastfeeding. 27, 28 However, our data show that babies in the dextrose gel group needed fewer formula feeds and less expressed breastmilk than did those in the feeding only group. If the mother's intention was to breastfeed and the baby was hypoglycaemic, mothers were encouraged to either feed the baby or express breastmilk. Some women could have felt pressured to provide breastmilk, which might have negatively aff ected the establishment of breastfeeding. Furthermore, fewer babies in the dextrose gel group received additional dextrose, either intravenously or as open-label gel after treatment failure, than did those in the placebo group; thus, babies in the dextrose gel group received less additional clinical intervention, and therefore spent less time separated from their parents. All of these factors might have contributed to our fi nding that at 2 weeks of age, formula feeding was less common in babies receiving dextrose gel than in those receiving placebo. We postulate that provision of a treatment that allows the mother and baby to remain together while supporting metabolic transition to extrauterine life could reduce maternal anxiety and support establishment of breastfeeding in the early postnatal period.
Perhaps surprisingly, continuous glucose monitoring showed that time taken for the interstitial glucose concentration to recover after gel treatment was similar in both groups. However, these fi ndings are from a subset of babies who had continuous glucose monitor ing, and of these, fewer than half the treatment episodes were available for analysis. There were two reasons for this restricted availability: (1) although the continuous glucose monitor was placed as soon after birth as possible, it takes 1 h to initialise, meaning that in 152 cases the fi rst gel treatment was given before continuous glucose data were available; (2) we noted 24 episodes of hypoglycaemia when, although the blood and interstitial glucose concentrations were less than 2·6 mmol/L at the time of diagnosis of the hypoglycaemic episode, the interstitial glucose concentration was 2·6 mmol/L or more at the time of gel administration, and therefore the secondary outcomes could not be established.
One potential risk of administration of dextrose gel is the possibility of the occurrence of rebound hypoglycaemia secondary to stimulation of insulin secretion. Lilien and colleagues 15 reported that a minibolus of 200 mg/kg intravenous dextrose improved blood glucose concentrations without hyperglycaemia. We chose the same dose for administration of buccal glucose, and also noted that rebound hypoglycaemia was uncommon and occurred with similar frequency in both groups. How ever, consistent with the overall fi ndings that dextrose gel reduced treatment failure, recurrent hypoglycaemia was less common in babies who received dextrose gel when measured by continuous interstitial glucose monitoring, despite these babies receiving less frequent feeds than those in the placebo gel group. Furthermore, babies who received dextrose gel seemed to spend less time overall in a hypoglycaemic state than did babies who received placebo gel, although this fi nding was not statistically signifi cant.
Babies in this trial were similar to most of those who are at risk of hypoglycaemia in the immediate neonatal period. Although dextrose gel did not decrease admission to the neonatal intensive-care unit in this study, most likely because babies were admitted for various reasons other than hypoglycaemia, it did reduce admis sion for hypoglycaemia. This fi nding suggests that, in babies at risk of hypoglycaemia but without other comor bidities, treatment with dextrose gel could avert the need for admission to intensive care, thus reducing costs and
Panel: Research in context
Systematic review
We searched PubMed and Cumulative Index to Nursing and Allied Health Literature to May 1, 2013, with keywords infant/newborn, hypoglycaemia, glucose, buccal, sublingual, treatment, and Hypostop. Our search did not reveal any systematic reviews of this treatment. The only randomised trial, available only in abstract, reported that treatment of babies admitted to neonatal intensive care with 400 mg/kg dextrose gel did not increase blood glucose concentrations, although for 75 randomly assigned babies, power to detect relevant clinical outcomes was restricted.
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Interpretation Treatment with 40% dextrose gel 200 mg/kg was more eff ective than feeding alone for reversal of neonatal hypoglycaemia in at-risk late preterm and term babies in the fi rst 48 h after birth. This treatment could help to avoid admission to neonatal intensive-care units in babies not needing admission for other reasons, and seems to support breastfeeding, partly by reducing the use of formula in the neonatal period. Dextrose gel did not increase the risk of rebound or recurrent hypoglycaemia, was well tolerated, and was not associated with adverse eff ects. Because this treatment is inexpensive and simple to administer, it should be considered for fi rst-line management of late preterm and term hypoglycaemic babies in the fi rst 48 h after birth.
keeping mother and baby together. We cannot extrapolate from our data whether dextrose gel is eff ective treatment in babies of other gestational or postnatal ages. Neither can we establish whether the dose we have used is ideal.
Dextrose gel treatment has various advantages including ease of administration and low cost. Babies tolerated both the administration of the gel and the gel itself. Both parents and staff reported gel treatment to be acceptable and simple to administer. Dextrose gel is inexpensive and can be purchased commercially for roughly US$70 per 100 mL or $2 per baby, can easily be made in the hospital pharmacy, and is stable at room temperature. Therefore, the gel could also be useful in resource-poor settings where hypoglycaemia is common and under diagnosed. 8, 9, 29 Dextrose gel should be considered for fi rst-line manage ment of late preterm and term hypoglycaemic babies in the fi rst 48 h after birth.
Contributors
DLH and PJW contributed to the literature search, study design, data collection, analysis, and interpretation. DLH wrote the fi rst draft of the manuscript; and contributed to subsequent revisions. MS and JGC contributed to the data analysis and interpretation of the continuous glucose monitoring data and the fi nal manuscript. JEH contributed to the study design, data analysis and interpretation, and to writing all versions of the manuscript, and had overall responsibility for the study.
Confl icts of interests
We declare that we have no confl icts of interest.
